APA (7th ed.) Citation

R, B., J, M., E, M., L, A., I, T., L, S., . . . RK, K. (2026). Efficacy and safety of long-acting injectable paliperidone palmitate 1-month and 3-month formulations in the maintenance treatment of schizophrenia: A single-arm, open-label, interventional study in Rwandan healthcare settings. BMJ open, 16(6), e109753. https://doi.org/10.1136/bmjopen-2025-109753

Chicago Style (17th ed.) Citation

R, Bizoza, Mehawej J, Musoni-Rwililiza E, Alphs L, Turkoz I, Sun L, Killion L, Decotelli-Mendes C, and Knight RK. "Efficacy and Safety of Long-acting Injectable Paliperidone Palmitate 1-month and 3-month Formulations in the Maintenance Treatment of Schizophrenia: A Single-arm, Open-label, Interventional Study in Rwandan Healthcare Settings." BMJ Open 16, no. 6 (2026): e109753. https://doi.org/10.1136/bmjopen-2025-109753.

MLA (9th ed.) Citation

R, Bizoza, et al. "Efficacy and Safety of Long-acting Injectable Paliperidone Palmitate 1-month and 3-month Formulations in the Maintenance Treatment of Schizophrenia: A Single-arm, Open-label, Interventional Study in Rwandan Healthcare Settings." BMJ Open, vol. 16, no. 6, 2026, p. e109753, https://doi.org/10.1136/bmjopen-2025-109753.